Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266363 · ClinicalTrials.gov registry record
Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma
A clinical trial of ESCC, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT07266363: Recruiting study of ESCC, sponsored by City of Hope Medical Center.
NCT07266363 is a study of ESCC that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 600 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07266363, a study of ESCC, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability to detect early-stage lesions. To address this clinical need, the SYNERGY study seeks to develop a non-invasive, blood-based biomarker assay that integrates cell-free microRNAs (cf-miRNAs) and exosomal microRNAs (exo-miRNAs) to detect ESCC at an early and potentially curable stage. This multicenter translational study includes discovery, training, and validation phases using preoperative plasma or serum samples. By combining the tumor specificity of exosomal miRNAs with the systemic sensitivity of cf-miRNAs, SYNERGY aims to construct a robust diagnostic model with high sensitivity and specificity for early ESCC detection.
Primary Outcome
Comparison of Pathological Diagnosis and the SYNERGY Assay
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Small RNA sequencing of exo- and cf-miRNAs
- DIAGNOSTIC_TEST RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay)
- DIAGNOSTIC_TEST PCR-based validation (SYNERGY assay)
Study Locations (1)
California
- City of Hope Medical Center - Monrovia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2026-06-18 |
What NCT07266363 shows while recruiting
NCT07266363 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with ESCC appearing as the primary indexed condition, and to 3 interventions - of which Small RNA sequencing of exo- and cf-miRNAs is the first listed.
NCT07266363 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07266363 about?
NCT07266363 is a clinical study titled "Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma". Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability to detect early-stage lesions. To address this clinical need, the SYNER...
What is the current status of trial NCT07266363?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-01-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07266363 study?
This clinical trial studies the following conditions: ESCC.
What interventions are being tested in trial NCT07266363?
The interventions under investigation include: Small RNA sequencing of exo- and cf-miRNAs (DIAGNOSTIC_TEST), RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay) (DIAGNOSTIC_TEST), PCR-based validation (SYNERGY assay) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07266363?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266363 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ESCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI